Incyte Corporation (NASDAQ:INCY) is one of the best immunotherapy stocks to buy according to hedge funds. Jefferies reiterated a Buy rating on Incyte Corporation (NASDAQ:INCY) on February 11, setting ...

While Jakafi remains the top-selling drug for INCY, the market has historically discounted INCY stock due to Jakafi's late 2028 patent cliff (although Jakafi's sales kept growing). In Q3 2025, ...

Investors in Incyte Corporation (Symbol: INCY) saw new options become available this week, for the February 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Fintel reports that on November 24, 2025, Barclays maintained coverage of Incyte (NasdaqGS:INCY) with a Overweight recommendation. Analyst Price Forecast Suggests 7.38% Downside As of November 17, ...

Incyte Corporation (NASDAQ:INCY) ranks among the most undervalued NASDAQ stocks to buy now. Citizens JMP reaffirmed its Market Perform rating on Incyte Corporation (NASDAQ:INCY) on September 18 after ...

Below is Validea's guru fundamental report for INCYTE CORP (INCY). Of the 22 guru strategies we follow, INCY rates highest using our Multi-Factor Investor model based on the published strategy of Pim ...

Incyte's recent earnings call disappointed the market, causing a 10.52% drop, but management's bullish comments and no debt position suggest a promising future. Technically, INCY is currently below ...